Glenmark Generics gets US FDA nod

The company gets the US health regulatory nod for Prilosec, a drug used for treatment of ulcer


The drug has received final approval for 10, 20, and 40 mg strengths of Omeprazole

Glenmark Generics has announced that it has received approval from the United States Food and Drugs Administration (US FDA) to market generic version of AstraZeneca's Prilosec, a drug used for treatment of ulcer.

"Glenmark Generics (GGI) has been granted the final abbreviated new drug approval (ANDA) from the US FDA for Omeprazole Delayed Release Capsules, their generic version of Prilosec by AstraZeneca," the company said in a statement.

The company has received final approval for 10, 20, and 40 mg strengths of Omeprazole.

According to IMS sales data, for the 12 month period ending September 2014,  Omeprazole garnered annual sales of approximately $520 million.


Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email